These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32666469)

  • 1. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
    Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
    Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
    Meng G; Wang J; Wang X; Wang Y; Wang Z
    Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
    Zhang Q; Zhao YZ; Ma HH; Wang D; Cui L; Li WJ; Wei A; Wang CJ; Wang TY; Li ZG; Zhang R
    Blood; 2022 Jun; 139(24):3493-3504. PubMed ID: 35344583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 8. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
    Song Y; Wang J; Wang Y; Wang Z
    Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
    Xu Y; Li W; Gan J; He X; Huang X
    Ann Hematol; 2023 Dec; 102(12):3325-3333. PubMed ID: 37787838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
    Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
    Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
    Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
    Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
    J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
    Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
    Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
    Jianguo L; Zhixuan Z; Rong L; Xiaodong S
    Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children.
    Cheng CN; Chu WY; Chang KC; Chen JS
    J Formos Med Assoc; 2022 Nov; 121(11):2351-2355. PubMed ID: 35123848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis and follow-up study of Epstein-Barr virus associated-hemophagocytic lymphohistiocytosis in childhood].
    Lu G; Xie ZD; Shen KL; Wu RH; Jin YK; Yang S; Liu CY
    Zhonghua Er Ke Za Zhi; 2010 Feb; 48(2):121-6. PubMed ID: 20426937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
    Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
    Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
    Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.